Pipeline

Innovation in progress

Commercial product

ADASUVE® Staccato® loxapine

For the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Full prescribing information, including boxed warning, at ADASUVE.com or the EMA website.

Preclinical
Phase 1
Phase 2
Phase 3
NDA/MAA
Marketed

Active programs in development with partners

Staccato® alprazolam

For the acute treatment of epileptic seizures

Preclinical
Phase 1
Phase 2
Phase 3
NDA/MAA
Marketed

Active programs led by Alexza

Staccato® apomorphine

For the rapid, acute treatment of OFF episodes in patients with Parkinson’s disease on stable anti-Parkinson medication

Preclinical
Phase 1
Phase 2
Phase 3
NDA/MAA
Marketed

Staccato® granisetron

For the acute treatment of cyclic vomiting syndrome

Preclinical
Phase 1
Phase 2
Phase 3
NDA/MAA
Marketed

Inactive programs

Staccato® zaleplon

For the treatment of middle of the night awakening

Preclinical
Phase 1
Phase 2
Phase 3
NDA/MAA
Marketed

Migraine

Preclinical
Phase 1
Phase 2
Phase 3
NDA/MAA
Marketed

Smoking cessation

Preclinical
Phase 1
Phase 2
Phase 3
NDA/MAA
Marketed

For more information about our programs click here.

For more information about pipeline opportunities click here.

To discuss partnership and licensing opportunities, please contact our Business Development Group.

Staccato OBT Staccato Logo